- Cymabay (NASDAQ: CBAY) is developing PPAR-delta agonist, Seladelpar in treating non-alcoholic steatohepatitis, NASH.
- Phase 2b data in this indication is expected towards the end of June this year and is expected to a price-moving binary event, with an expected move of approx. 35%.
- In this brief note, I provide an options strategy to play this event that could return 30% in less than 4 weeks..
To read more, take a free trial of FAtrader.